Summit Therapeutics PLC SMMT

15.61 (0.77) (4.70%) as of 25 Sep
Market cap
$13.1B
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
6.96 7.41 9.87 3.80
Current Ratio
6.96 7.41 9.87 3.80
Net Debt/EBITDA
3.13 3.16 3.12 1.02
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.65 0.65 0.47 0.40
Capex/Depreciation
(19.76) (5.57) (3.90) (1.69)
Interest Coverage
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.01
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.18) (0.16) (0.14) (0.13)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.18) (0.16) (0.14) (0.13)
Cash per Share
0.89 0.77 0.95 0.32
Shareholders Equity per Share
0.81 0.70 0.88 0.26
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
0.81 0.70 0.88 0.26
Free Cash Flow
(142.03) (122.54) (102.10) (93.15)
Working Capital
617.01 533.33 647.31 181.54
Capital Expenditures
(0.91) (0.24) (0.16) (0.07)
Net Current Asset Value
598.38 514.67 627.98 177.00
EV/EBIT
— — — —
Capex to Sales
0.00 0.00 0.00 0.00
Net Profit Margin
0.00% 0.00% 0.00% 0.00%
Other line items
Average Receivables
20.32 13.33 8.81 5.33
Average Payables
22.94 16.27 12.46 12.75
Average Assets
538.11 515.84 593.37 382.29
Average Common Equity
444.71 445.13 523.80 315.09

Fold the line items

Columns are period end dates